All Updates

All Updates

icon
Filter
Regulation/policy
Illumina to divest GRAIL after US Fifth Circuit Court of Appeals decision
Precision Medicine
Dec 17, 2023
This week:
Funding
MeliBio receives strategic investment from Future Food Fund
Alternative Ingredients
Yesterday
Product updates
Catchfree launches microalgae-based shrimp alternative
Plant-based Meat
Yesterday
Product updates
AQUA Cultured Foods introduces fermentation-based raw tuna alternative
Plant-based Meat
Yesterday
Management news
SDI Element Logic rebrands as Element Logic
Logistics Tech
Yesterday
Geographic expansion
Wayve opens office and commences testing of automated driving features in US
Auto Tech
Yesterday
Partnerships
Qualcomm and Google partner to develop AI-driven automotive solutions
Auto Tech
Yesterday
Product updates
Meta AI releases LayerSkip to accelerate inference in LLMs
Generative AI Infrastructure
Yesterday
Funding
Freeform secures funding from NVIDIA's NVentures
Additive Manufacturing
Oct 22, 2024
Product updates
Flexxbotics announces compatibility with LMI Technologies for quality inspection
Smart Factory
Oct 22, 2024
Funding
Oxla raises USD 11 million in seed funding to drive commercialization
Data Infrastructure & Analytics
Oct 22, 2024
Precision Medicine

Precision Medicine

Dec 17, 2023

Illumina to divest GRAIL after US Fifth Circuit Court of Appeals decision

Regulation/policy

  • Illumina announced that the company will divest GRAIL via a third-party sale or capital markets transaction, as per the European Commission's divestiture order, to finalize the terms by the second quarter of 2024.

  • On December 15, the US Fifth Circuit Court of Appeals issued its decision relating to Illumina vs. the Federal Trade Commission. Considering this opinion, Illumina has opted not to pursue further appeals of this decision. 

  • GRAIL would continue to be held separately, along with committed funding from Illumina for the company's business through the divestment process. Prior to this, Illumina had spun off GRAIL in 2016 but retained a 12% stake and subsequently reacquired the company in 2021.

  • GRAIL has developed the Galleri test, the first clinically validated MCED test that reportedly can detect a signal shared by more than 50 types of cancer with 99.5% specificity and predict the cancer signal origin with high accuracy to help guide the next steps. 

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.